Vitality Watch

Dossier pubmed review 09-nov-2026
Narrative review or expert overview without new data

Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy.

Key claim: Senescence-targeted CAR-T immunotherapy offers precise clearance of pathological senescent cells and extends preclinical healthspan, though clinical translation faces challenges with antigen specificity and immunosuppressive aged microenvironments.

Abstract

Cellular senescence acts as a core driver of chronic diseases and tissue degeneration. Conventional small-molecule senolytics face critical limitations including poor target specificity and off-target toxicity when eliminating heterogeneous senescent cell populations. This review systematically discusses senescence-targeted engineered chimeric antigen receptor (CAR)-T immunotherapy, which achieves targeted clearance of pathological senescent cells by recognising specific surface markers. It summarises target-antigen evaluation frameworks, analyzes aged immunosuppressive microenvironment barriers and corresponding engineering strategies, and outlines composite efficacy assessment systems and tiered biomarker-monitoring workflows. Key translational bottlenecks such as imperfect antigen specificity and immune escape are also addressed. Preclinical studies verify organ function restoration and healthspan extension, while clinical evidence remains limited. Future integration of CAR-T technology with smart nanocarriers, synthetic biology and artificial intelligence will promote its clinical translation for senescence-associated disorders.

Why this matters

The review develops the research case for CAR-T cells as targeted senolytics [expert-opinion], but supplies no media or community evidence of wider adoption. Reported healthspan benefits remain preclinical [animal-model], while the review identifies unresolved target-specificity and aged-microenvironment barriers [expert-opinion]; its translational roadmap is not evidence of human rejuvenation.

Source

Link

Briefing card

Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy.
Stage: review · pubmed · 09-nov-2026

If you encounter claims that senolytic CAR-T therapy extends human healthspan, this review does not establish that benefit.

Senescence-targeted CAR-T immunotherapy offers precise clearance of pathological senescent cells and extends preclinical healthspan, though clinical translation faces challenges with antigen specificity and immunosuppressive aged microenvironments.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.ebiom.2026.106540

build build 880 · 2bcef25 · 2026-11-18